title: Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs.
abstract: Resolution of acute inflammation is an active process that involves the biosynthesis of specialized proresolving lipid mediators. Among them, resolvin D1 (RvD1) actions are mediated by two G protein-coupled receptors (GPCRs), ALX/FPR2 and GPR32, that also regulate specific microRNAs (miRNAs) and their target genes in novel resolution circuits. We report the ligand selectivity of RvD1 activation of ALX/FPR2 and GPR32. In addition to RvD1, its aspirin-triggered epimer and RvD1 analogs each dose dependently and effectively activated ALX/FPR2 and GPR32 in GPCR-overexpressing β-arrestin systems using luminescence and electric cell-substrate impedance sensing. To corroborate these findings in vivo, neutrophil infiltration in self-limited peritonitis was reduced in human ALX/FPR2-overexpressing transgenic mice that was further limited to 50% by RvD1 treatment with as little as 10 ng of RvD1 per mouse. Analysis of miRNA expression revealed that RvD1 administration significantly up-regulated miR-208a and miR-219 in exudates isolated from ALX/FPR2 transgenic mice compared with littermates. Overexpression of miR-208a in human macrophages up-regulated IL-10. In comparison, in ALX/FPR2 knockout mice, RvD1 neither significantly reduced leukocyte infiltration in zymosan-induced peritonitis nor regulated miR-208a and IL-10 in these mice. Together, these results demonstrate the selectivity of RvD1 interactions with receptors ALX/FPR2 and GPR32. Moreover, they establish a new molecular circuit that is operative in the resolution of acute inflammation activated by the proresolving mediator RvD1 involving specific GPCRs and miRNAs.
authors.affiliation: Center for Experimental Therapeutics and Reperfusion Injury, Harvard Institutes of Medicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.
authors.forename: Sriram
authors.initials: S
authors.lastname: Krishnamoorthy
authors.forename: Antonio
authors.initials: A
authors.lastname: Recchiuti
authors.forename: Nan
authors.initials: N
authors.lastname: Chiang
authors.forename: Gabrielle
authors.initials: G
authors.lastname: Fredman
authors.forename: Charles N
authors.initials: CN
authors.lastname: Serhan
mesh_terms: D000208:Acute Disease; D000818:Animals; D019390:Arrestins / Q000378:metabolism; D002478:Cells, Cultured; D004281:Docosahexaenoic Acids / Q000494:pharmacology / Q000502:physiology* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D017097:Electric Impedance; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007249:Inflammation / Q000235:genetics / Q000378:metabolism*; D016753:Interleukin-10 / Q000096:biosynthesis / Q000235:genetics; D008024:Ligands; D008264:Macrophages / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D035683:MicroRNAs / Q000235:genetics*; D020556:Neutrophil Infiltration / Q000187:drug effects / Q000502:physiology; D010538:Peritonitis / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D044042:Receptors, Formyl Peptide / Q000502:physiology; D043562:Receptors, G-Protein-Coupled / Q000502:physiology*; D044067:Receptors, Lipoxin / Q000502:physiology; D015854:Up-Regulation / Q000187:drug effects; D000071557:beta-Arrestins
chemical_list: D019390:Arrestins; C105101:FPR2 protein, human; C114479:GPR32 protein, human; D008024:Ligands; C534451:MIRN20a microRNA, human; D035683:MicroRNAs; D044042:Receptors, Formyl Peptide; D043562:Receptors, G-Protein-Coupled; D044067:Receptors, Lipoxin; D000071557:beta-Arrestins; C518399:resolvin D1; D016753:Interleukin-10; D004281:Docosahexaenoic Acids